Paul E Croarkin1, M Albert Thomas2, John D Port3, Joshua M Baruth4, Doo-Sup Choi5, Osama A Abulseoud1, Mark A Frye1. 1. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. 2. Department of Radiology, Psychiatry, and Biomedical Engineering, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. 3. Department of Radiology, Mayo Clinic, Rochester, MN, USA. 4. University of Louisville School of Medicine, Louisville, KY, USA. 5. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Abstract
OBJECTIVES: The aim of the present study was to examine N-acetylaspartate (NAA), a general marker of neuronal viability, and total NAA (tNAA), the combined signal of NAA and N-acetylaspartylglutamate, in bipolar depression before and after lamotrigine treatment. Given that NAA is synthesized through direct acetylation of aspartate by acetyl-coenzyme A-l-aspartate-N-acetyltransferase, we hypothesized that treatment with lamotrigine would be associated with an increase in NAA level. METHODS: Patients with bipolar depression underwent two-dimensional proton magnetic resonance spectroscopy of the anterior cingulate at baseline (n = 15) and after 12 weeks of lamotrigine treatment (n = 10). A group of age-matched healthy controls (n = 9) underwent scanning at baseline for comparison. RESULTS: At baseline, patients with bipolar depression had significantly lower NAA [mean standard deviation (SD) = 1.13 (0.21); p = 0.02] than controls [mean (SD) = 1.37 (0.27)]. Significant increases in NAA [mean (SD) = 1.39 (0.21); p = 0.01] and tNAA [mean (SD) = 1.61 (0.25); p = 0.02] levels were found after 12 weeks of lamotrigine treatment. CONCLUSIONS: These data suggest an NAA deficit in bipolar depression that is normalized after lamotrigine treatment. Future research is warranted to evaluate whether baseline NAA level is a potential biomarker for identifying lamotrigine response patterns and whether this functional brain change has an associated clinical response.
OBJECTIVES: The aim of the present study was to examine N-acetylaspartate (NAA), a general marker of neuronal viability, and total NAA (tNAA), the combined signal of NAA and N-acetylaspartylglutamate, in bipolar depression before and after lamotrigine treatment. Given that NAA is synthesized through direct acetylation of aspartate by acetyl-coenzyme A-l-aspartate-N-acetyltransferase, we hypothesized that treatment with lamotrigine would be associated with an increase in NAA level. METHODS:Patients with bipolar depression underwent two-dimensional proton magnetic resonance spectroscopy of the anterior cingulate at baseline (n = 15) and after 12 weeks of lamotrigine treatment (n = 10). A group of age-matched healthy controls (n = 9) underwent scanning at baseline for comparison. RESULTS: At baseline, patients with bipolar depression had significantly lower NAA [mean standard deviation (SD) = 1.13 (0.21); p = 0.02] than controls [mean (SD) = 1.37 (0.27)]. Significant increases in NAA [mean (SD) = 1.39 (0.21); p = 0.01] and tNAA [mean (SD) = 1.61 (0.25); p = 0.02] levels were found after 12 weeks of lamotrigine treatment. CONCLUSIONS: These data suggest an NAAdeficit in bipolar depression that is normalized after lamotrigine treatment. Future research is warranted to evaluate whether baseline NAA level is a potential biomarker for identifying lamotrigine response patterns and whether this functional brain change has an associated clinical response.
Authors: M A Thomas; K Yue; N Binesh; P Davanzo; A Kumar; B Siegel; M Frye; J Curran; R Lufkin; P Martin; B Guze Journal: Magn Reson Med Date: 2001-07 Impact factor: 4.668
Authors: G J Moore; J M Bebchuk; K Hasanat; G Chen; N Seraji-Bozorgzad; I B Wilds; M W Faulk; S Koch; D A Glitz; L Jolkovsky; H K Manji Journal: Biol Psychiatry Date: 2000-07-01 Impact factor: 13.382
Authors: Mark A Frye; M Albert Thomas; Kenneth Yue; Nader Binesh; Pablo Davanzo; Joseph Ventura; Joseph O'Neill; Barry Guze; John G Curran; Jim Mintz Journal: Psychiatry Res Date: 2007-03-07 Impact factor: 3.222
Authors: Rajakumar Nagarajan; Manoj K Sarma; April D Thames; Steven A Castellon; Charles H Hinkin; M Albert Thomas Journal: Int J Hepatol Date: 2012-07-12
Authors: A Irem Sonmez; Charles P Lewis; John D Port; Alejandra Cabello-Arreola; Caren J Blacker; Bhedita J Seewoo; Alastair J McKean; Jarrod M Leffler; Mark A Frye; Paul E Croarkin Journal: J Child Adolesc Psychopharmacol Date: 2020-11-11 Impact factor: 2.576
Authors: Marin Veldic; Vincent Millischer; John D Port; Ada Man-Choi Ho; Yun-Fang Jia; Jennifer R Geske; Joanna M Biernacka; Lena Backlund; Susan L McElroy; David J Bond; J Carlos Villaescusa; Michelle Skime; Doo-Sup Choi; Catharina Lavebratt; Martin Schalling; Mark A Frye Journal: Transl Psychiatry Date: 2019-05-23 Impact factor: 6.222
Authors: Charles P Lewis; John D Port; Caren J Blacker; A Irem Sonmez; Bhedita J Seewoo; Jarrod M Leffler; Mark A Frye; Paul E Croarkin Journal: Transl Psychiatry Date: 2020-04-23 Impact factor: 6.222
Authors: Louise Martens; Luisa Herrmann; Lejla Colic; Meng Li; Anni Richter; Gusalija Behnisch; Oliver Stork; Constanze Seidenbecher; Björn H Schott; Martin Walter Journal: Sci Rep Date: 2021-03-24 Impact factor: 4.379
Authors: Beata R Godlewska; Uzay E Emir; Charles Masaki; Theodoras Bargiotas; Philip J Cowen Journal: J Affect Disord Date: 2018-12-25 Impact factor: 4.839
Authors: Tara L White; Meghan A Gonsalves; Ronald A Cohen; Ashley D Harris; Mollie A Monnig; Edward G Walsh; Adam Z Nitenson; Eric C Porges; Damon G Lamb; Adam J Woods; Cara B Borja Journal: Neuroimage Date: 2020-10-27 Impact factor: 6.556